DK2971039T3 - Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer - Google Patents

Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer Download PDF

Info

Publication number
DK2971039T3
DK2971039T3 DK14768084.7T DK14768084T DK2971039T3 DK 2971039 T3 DK2971039 T3 DK 2971039T3 DK 14768084 T DK14768084 T DK 14768084T DK 2971039 T3 DK2971039 T3 DK 2971039T3
Authority
DK
Denmark
Prior art keywords
pseudotype
vsv
transduction
cells
memory
Prior art date
Application number
DK14768084.7T
Other languages
English (en)
Inventor
Mei Xu
Matthew Rein Scholz
Eric J Herbig
Original Assignee
Immusoft Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusoft Corp filed Critical Immusoft Corp
Application granted granted Critical
Publication of DK2971039T3 publication Critical patent/DK2971039T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14768084.7T 2013-03-14 2014-03-14 Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer DK2971039T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785490P 2013-03-14 2013-03-14
PCT/US2014/027910 WO2014152832A1 (en) 2013-03-14 2014-03-14 Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors

Publications (1)

Publication Number Publication Date
DK2971039T3 true DK2971039T3 (da) 2020-04-06

Family

ID=51581331

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14768084.7T DK2971039T3 (da) 2013-03-14 2014-03-14 Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer

Country Status (9)

Country Link
US (3) US10240125B2 (da)
EP (1) EP2971039B1 (da)
JP (5) JP6392315B2 (da)
CA (1) CA2906674C (da)
DK (1) DK2971039T3 (da)
ES (1) ES2786253T3 (da)
HK (1) HK1220230A1 (da)
PT (1) PT2971039T (da)
WO (1) WO2014152832A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2786253T3 (es) * 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
PL3234107T3 (pl) 2014-12-19 2023-01-16 Immusoft Corporation Limfocyty b do dostarczania in vivo środków terapeutycznych
CA2981077A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016201077A1 (en) * 2015-06-12 2016-12-15 Emory University Growth and survival compositions for cells capable of producing antibodies and methods related thereto
IL266208B2 (en) * 2016-10-23 2024-05-01 Berkeley Lights Inc Methods for scanning lymphocyte-B cells
EP3615045A4 (en) * 2017-04-27 2021-01-13 Immusoft Corporation B LYMPHOCYTES FOR ADMINISTRATION IN VIVO
US11125757B2 (en) 2017-05-26 2021-09-21 Emory University Methods of culturing and characterizing antibody secreting cells
CA3093716A1 (en) 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
AU2020388676B2 (en) * 2019-11-21 2024-07-18 Emulate Inc. Antibody producing microfluidic devices
KR102539610B1 (ko) * 2020-01-22 2023-06-02 한국생명공학연구원 메모리 b 세포 특이적 분화 유도 방법 및 이의 활용
EP4429659A1 (en) * 2021-11-11 2024-09-18 The General Hospital Corporation Methods for defining stages and progression of amyotrophic lateral sclerosis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0276820A (ja) 1988-06-15 1990-03-16 Ajinomoto Co Inc 骨髄移植療法支持剤
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
US5297983A (en) 1991-07-15 1994-03-29 Albert Handtmann Maschinenfabrik Gmbh & Co., Kg Process and device for separating and placing a gut caterpillar on a filling tube
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
EP0938893B1 (en) 1993-08-10 2004-08-25 W.L. Gore & Associates, Inc. Cell encapsulating device
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
DE69630266T2 (de) 1995-06-07 2004-09-09 W.L. Gore & Associates, Inc., Newark Implantierbare aufnahmevorrichtung für ein therapeutisches gerät
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
AU2002311753B2 (en) 2001-02-15 2008-04-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
CA2438500C (en) 2001-02-19 2009-09-08 Pola Chemical Industries Inc. Composition for electroporation
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
EP2368982A3 (en) 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2004037977A2 (en) 2002-09-05 2004-05-06 California Institute Of Thechnology Use of chimeric nucleases to stimulate gene targeting
US20070134796A1 (en) 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
WO2006029196A1 (en) * 2004-09-08 2006-03-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth Transcytosis of adeno-associated viruses
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
JP4937138B2 (ja) 2005-01-05 2012-05-23 エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
CA2538208A1 (en) 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
US20090263900A1 (en) 2008-04-14 2009-10-22 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
AU2006315274B2 (en) 2005-11-17 2012-07-05 Biogen Ma Inc. Platelet aggregation assays
FI1974017T4 (fi) 2005-12-09 2023-09-14 Välineitä ja menetelmiä, joilla voidaan vaikuttaa vasta-ainetta tuottavien solujen stabiliteettiin
US7799555B2 (en) 2006-02-10 2010-09-21 Bio-Rad Laboratories, Inc. Apparatus for high-throughput electroporation
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
EP2205752B1 (en) 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
US8551780B2 (en) 2008-02-01 2013-10-08 H. Lee Moffitt Cancer Center & Research Institute, Inc. Electroporation buffer composition and method of use
KR20160015400A (ko) 2008-08-22 2016-02-12 상가모 바이오사이언스 인코포레이티드 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
JP5726744B2 (ja) * 2008-11-21 2015-06-03 カリフォルニア インスティチュート オブ テクノロジー 生体外におけるヒトｂリンパ球産生培養システム
US9074223B2 (en) * 2010-01-08 2015-07-07 Immusoft Corporation Vectors and methods for transducing B cells
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
KR101637933B1 (ko) 2010-03-15 2016-07-08 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 포유동물 세포로의 유전자 도입효율의 향상제
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
ES2434256T3 (es) 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
ES2604356T3 (es) 2011-12-14 2017-03-06 Yeda Research And Development Co. Ltd. Subpoblación de monocitos humanos para el tratamiento de lesiones del sistema nervioso central
AU2014209178B2 (en) 2013-01-25 2018-11-08 Takeda Pharmaceutical Company Limited Follistatin in treating Duchenne muscular dystrophy
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
US10842886B2 (en) 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle
PL3234107T3 (pl) 2014-12-19 2023-01-16 Immusoft Corporation Limfocyty b do dostarczania in vivo środków terapeutycznych
CA2981077A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016187017A1 (en) 2015-05-15 2016-11-24 Mcivor R Scott Adeno-associated for therapeutic delivery to central nervous system
CA3093716A1 (en) 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength

Also Published As

Publication number Publication date
JP2023105218A (ja) 2023-07-28
HK1220230A1 (zh) 2017-04-28
EP2971039A4 (en) 2016-10-12
PT2971039T (pt) 2020-05-06
EP2971039A1 (en) 2016-01-20
CA2906674C (en) 2023-01-10
US20190241870A1 (en) 2019-08-08
ES2786253T3 (es) 2020-10-09
EP2971039B1 (en) 2020-01-01
JP2020062058A (ja) 2020-04-23
US20230013198A1 (en) 2023-01-19
JP7499798B2 (ja) 2024-06-14
WO2014152832A1 (en) 2014-09-25
JP2022048252A (ja) 2022-03-25
JP6689897B2 (ja) 2020-04-28
JP2018075039A (ja) 2018-05-17
US10240125B2 (en) 2019-03-26
JP6392315B2 (ja) 2018-09-19
CA2906674A1 (en) 2014-09-25
US11352603B2 (en) 2022-06-07
US20160046908A1 (en) 2016-02-18
JP2016513476A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
DK2971039T3 (da) Fremgangsmåder til in vitro-differentiering af hukommelses-b-celler og transduktion med vsv-g-pseudotypeomdannede virusvektorer
DK3421590T3 (da) Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK2953969T3 (da) Anti-IL-17A-antistoffer og deres anvendelse til behandling af autoimmune og inflammatoriske forstyrrelser
DK3462569T3 (da) Batteri og ubemandet luftfartøj med batteri
DK2970398T3 (da) Præfusions-rsv-f-proteiner og anvendelse deraf
DK3083616T3 (da) Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
DK3322425T3 (da) Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
DK3027204T3 (da) Flerdelte signaleringsproteiner og anvendelser deraf
DK3421486T5 (da) Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
DK2970898T3 (da) Fremstilling og anvendels af røde blodceller
DK3409083T3 (da) Forbedringer af og i forbindelse med datacentre
DK3200791T3 (da) Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
DK2805670T3 (da) Forbedringer af og i sammenhæng med oftalmoskoper
DK3303778T3 (da) Forbedringer i energiopbevaring
DK3065759T3 (da) Immunosuppressive midler og deres anvendelse i terapi
FR3001457B1 (fr) Nouveaux polymeres peignes utilisables en cosmetique et detergence
DK2955777T3 (da) Brændselscelle og fremgangsmåde til fremstilling af samme
DK2970843T3 (da) Fremgangsmåder til frembringelse af cellebank med høj densitet
DK3269809T3 (da) MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
DK3104717T3 (da) Saccharosereduktion og generering af uopløselige fibre i juice
DK3356444T3 (da) Med silikoneharpiks modificerede isocyanatoalkylalkoxysilan-addukter og deres anvendelse
DK3297063T3 (da) Kompositmembran og lithium-ion-batteri dermed
DK3619362T3 (da) Forbedringer af og i forbindelse med barrierer
DK2880053T3 (da) Lindring af vævsskade og fibrose via anti-LTBP4-antistof
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf